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The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, 
is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is 
a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time 
reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 
around the world. Korean Society for Laboratory Medicine and the Korea Centers for Dis-
ease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical labo-
ratories in Korea. These guidelines are based on other related domestic and international 
guidelines, as well as expert opinions and include the selection of test subjects, selection 
of specimens, diagnostic methods, interpretation of test results, and biosafety.
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INTRODUCTION
In December 2019, a mass outbreak of Coronavirus disease 
2019 (COVID-19) occurred in Wuhan, Hubei Province, People’s 
Republic of China. Currently, the disease has spread to other 
regions of China and around the world [1]. In Korea, more than 
9,000 patients have been confirmed as of March 25, 2020.
The World Health Organization (WHO) officially changed the 
name of the disease to coronavirus disease 2019 (COVID-19) 
from 2019 novel coronavirus (2019-nCoV) infection on Febru-
ary 11, 2020. The International Committee on Taxonomy of Vi-
ruses has proposed the name severe acute respiratory syn-
drome Coronavirus 2 (SARS-CoV-2) for the causative agent of 
COVID-19 [2]. This document uses COVID-19 and SARS-CoV-2, 
as well as 2019-nCoV infection as appropriate. 
This document provides guidelines for diagnosing COVID-19 
in human specimens. Some contents of this document, includ-
ing new test methods, specimen selection, and biosafety rec-
ommendations, may be subject to revision later, with the emer-
gence of new scientific evidence and based on expert review. 
The guidelines presented here are based on the “Korea Labo-
ratory Response and Preparedness for 2019 Novel Coronavirus 
Molecular Testing in Clinical Laboratories” project, which is a 
commissioned project aimed at establishing and managing CO-
VID-19 diagnosis in hospital laboratories and commercial labo-
ratory centers. All copyrights to these guidelines are owned by 
Korean Society for Laboratory Medicine (KSLM) and the Korea 
Centers for Disease Control and Prevention (KCDC).
 
CASE DEFINITION
The case definition is based on the 7th Edition (March 15, 2020) 
of the Guidelines on Response to Coronavirus Disease 2019 
published by the KCDC [3]. This case definition applies to condi-
tions at a “serious stage” crisis alert level, in which COVID-19 
imported into Korea is spreading to local communities or 
throughout the nation. It may be revised later based on the inci-
dence of confirmed domestic cases, results of epidemiological 
studies, and the level of epidemics. The definition of a suspected 
case and patient under investigation (PUI) can be changed ac-
cording to newly updated information from the KCDC.
Confirmed case
Cases with confirmed infection according to the diagnostic crite-
ria, irrespective of the clinical manifestation (diagnostic tests: 
COVID-19 real-time RT-PCR, virus isolation).
Suspected case
Cases with fever (37.5°C or higher) and/or respiratory symptoms 
(cough, sore throat, etc.) within 14 days of being in close con-
tact with a confirmed case.
PUI
-  Cases suspected of having COVID-19 based on a physician’s 
opinion (e.g. pneumonia of unknown origin).
-  Cases with fever (37.5°C or higher) and/or respiratory symp-
toms (cough, sore throat, etc.) within 14 days of visiting 
China (including the Special Administrative Regions of Hong 
Kong and Macau) or other COVID-19-affected countries (as 
listed on the WHO website).
-  Cases showing epidemiological correlation with the domestic 
mass outbreak of COVID-19 and exhibiting fever (37.5°C or 
higher) and/or respiratory symptoms (cough, dyspnea, etc.) 
within 14 days. 
TEST INDICATIONS
COVID-19 real-time RT-PCR may be performed for the purposes of:
Confirming cases of suspected COVID-19
 Deciding on the release of confirmed COVID-19 patients 
from quarantine
The release criteria can be changed at any time according to 
newly updated information from the KCDC. See newly updated 
information on the KCDC website [3].
 Screening asymptomatic individuals in close contact with 
confirmed COVID-19 patients
Although the importance of diagnosis in asymptomatic individu-
als who have been in close contact with confirmed COVID-19 
patients remains unclear, diagnostic testing can be considered 
for the early detection of cases progressing to symptomatic in-
fection. 
 Differential diagnosis of cases with unknown respiratory 
syndromes
The diagnostic testing may be performed for patients exhibiting 
pneumonia or respiratory syndromes with fever in order to iden-
tify the cause of the disease and to differentiate the condition 
from COVID-19. 
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METHODS FOR LABORATORY DIAGNOSIS
Real-time RT-PCR
Globally, various real-time RT-PCR protocols have been pro-
posed for the diagnosis of COVID-19 [4–11]; these protocols 
differ in the genes they detect. Further studies are needed to 
identify the optimal real-time RT-PCR protocol for diagnosing 
COVID-19 (Table 1).
Of the various protocols, some examine two genes using a 
two-step interpretation algorithm [5, 8, 12]. In these protocols, 
the identification of one gene is used as a screening test, while 
that of the second gene is used as a confirmatory test. In con-
trast, the results of other protocols, which examine three or 
more genes, are considered positive only when all genes are 
detected. If one of the genes is not detected in these protocols, 
the results are often interpreted as indeterminate or negative. 
These guidelines were prepared based on the guidelines pro-
vided by the KCDC and the WHO [6], which recommend PCR 
amplification of the viral E gene as a screening test and amplifica-
tion of the RdRp region of the orf1b gene as a confirmatory test. 
As of March 13, 2020, KSLM and the KCDC recommend a 
positive result determination only when all the genes are de-
tected, even for tests using different genes from those men-
tioned in the above two guidelines. This recommendation is 
based on the opinions of numerous experts who observed non-
specific and weak amplification in the clinical specimens of pa-
tients who received final results of COVID-19 as negative.
Clinical laboratories are recommended not to use methods 
other than real-time RT-PCR (pan-coronavirus PCR, serological 
tests, etc.) [13], laboratory-developed tests, and reagents that 
are not approved for emergency use by the Korea Ministry of 
Food and Drug Safety for diagnostic purposes. 
EMERGENCY USE OF AUTHORIZED 
REAGENTS
As of March 13, 2020, several commercially available real-time 
RT-PCR reagents have been approved for emergency use in Ko-
rea for the in vitro diagnosis of COVID-19. Information on the 
approved reagents is available on the KCDC website (http://
www.cdc.go.kr). 
The emergency use authorization (EUA) system is designed 
to respond to novel or emerging infectious diseases and is 
known for rapid evaluation and deliberation in emergency 
cases. Therefore, testing with approved reagents requires strin-
gent and continuous quality control. The collection of data and 
specimens, as well as cross-testing of positive and negative 
specimens across laboratories are necessary to continuously 
analyze test performance. 
All clinical laboratories should transfer their test results and all 
positive specimens to the KCDC. This is to ensure the quality 
control of reagents with EUA and laboratory surveillance of in-
fectious diseases. 
SPECIMEN TYPES, SELECTION, AND 
COLLECTION
Types of specimens [13–18]
General information
Repetitive testing may be necessary to confirm COVID-19 in 
Table 1. Target genes of various real-time RT-PCR protocols (including the reagents approved for emergency use in Korea as of March 13, 
2020) [5–9]    
Authors, manufacturers Target gene Reference
Corman, et al. E, RdRp [6]
Chu, et al. orf1b, N [5]
Ministry of Public Health, Thailand N [7]
Institut Pasteur E, RdRp [8]
Centers for Disease Control and Prevention (USA) N [9]
PowerCheck 2019-nCoV* (Kogene biotech, Seoul, Korea) E, RdRp http://www.kogene.co.kr/
Allplex 2019-nCoV* (Seegene, Seoul, Korea) E, RdRp, N http://www.seegene.com/
nCoV Real-Time Detection* (SD biosensors, Suwon, Korea) E, RdRp http://sdbiosensor.com/
DiaPlexQ 2019-nCoV*† (Solgent, Daejeon, Korea) orf1a, N http://www.solgent.com/
Real-Q 2019-nCoV* (BioSewoom, Seoul, Korea) E, RdRp https://biosewoom.com
*authorized for emergency use in Korea, as of Mar 13, 2020; †The correct positions of the targets were not provided by the manufacturer. 
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suspected cases or PUIs. As the clinical significance of co-in-
fection caused by the causative agent of COVID-19 and other 
infectious diseases remains unclear, the collection of a sufficient 
quantity of clinical specimens with proper methods is recom-
mended. 
As the current knowledge on COVID-19 is limited, it is difficult 
to rule out infection based on a single negative test result, espe-
cially when the test is performed using an upper respiratory 
tract specimen. Even if the upper respiratory tract specimen 
tests negative, the collection and testing of lower respiratory 
tract specimens are strongly recommended, especially in cases 
of severe or progressive disease. 
The collection of specimens for diagnosis is recommended 
within seven days of symptom onset. See Table 2 for informa-
tion on specimen containers, transport conditions, and storage 
periods.
Upper respiratory tract specimen collection
Nasopharyngeal swab, oropharyngeal swab, nasopharyngeal 
aspirates, etc.
Lower respiratory tract specimen collection
Sputum*, bronchial washing, tracheal aspirates, transtracheal as-
pirates, bronchoalveolar lavage, transbronchial lung biopsy, etc.
*In cases with no purulent sputum, ensure that the individual 
breathes deeply and coughs straight into the container when 
providing the sputum specimen. Sputum induction is not rec-
ommended.
Specimen selection [4, 14, 15, 17, 18]
Asymptomatic patients and patients with mild symptoms
The collection of both nasopharyngeal swabs and oropharyn-
geal swabs is recommended; these should be placed together 
in the same viral transport medium (VTM) to increase the sensi-
tivity [14, 19]. However, the currently available VTM-swab sys-
tems are often designed for one swab. Therefore, specimen 
packaging and shipping should be conducted carefully, as there 
is a risk of leakage during transportation. When collecting only 
one specimen, a nasopharyngeal swab is recommended first. It 
may be necessary to collect lower respiratory tract specimens, 
such as sputum; however, sputum induction is not indicated. 
Table 2. Specimens for COVID-19 testing [4, 18, 19]    
Types of specimens Collection devices Transport conditions Storage conditions Comments
Upper respiratory tract specimens: 
 NP swab*, OP swab*, and NP aspirate 
Dacron or flocked swabs in VTM 4°C Within 5 days: 4°C
Longer than 5 days: -70°C
Lower respiratory tract specimen: 
 sputum*
Sterile container 4°C Within 48 hr: 4°C
Longer  than 48 hr: -70°C
Lower respiratory tract specimen: 
 bronchial washing*
Sterile container 4°C Within 48 hr: 4°C
Longer than 48 hr: -70°C
P athogens might be diluted; 
however, the specimen can be 
subjected to diagnostic testing
Lower respiratory tract specimens: 
 tracheal aspirate and transtracheal 
 aspirate
Sterile container 4°C Within 48 hr: 4°C
Longer than 48 hr: -70°C
Lower respiratory tract specimen: 
 lung biopsy
Sterile container with saline 4°C Within 48 hr: 4°C
Longer than 48 hr: -70°C
Serum† Serum separation test tube (SST): 
 adults and children, 3–5 mL; 
 infants, 1 mL
4°C Within 5 days: 4°C
Longer than 5 days: -70°C
F or serological tests, a pair of 
specimens is collected
A cute phase: within 7 days of 
symptom onset
C onvalescent period: 14 days 
after collection during acute 
phase
D ispensing of serum into another 
container should be conducted 
in a Class II or higher BSC
*Specimens recommended by the kit and approved by the Korea Ministry of Food and Drug Safety (MFDS) on March 13, 2020; †Specimens requiring ad-
vance consultation between the referrer and the laboratory.    
Abbreviations: VTM, viral transport medium; NP, nasopharyngeal; OP, oropharyngeal; BSC, biosafety cabinet.    
Hong KH, et al.
COVID-19 laboratory diagnosis guidelines in Korea
https://doi.org/10.3343/alm.2020.40.5.351 www.annlabmed.org  355
Patients with severe symptoms, patients with a productive cough, 
and intubated patients 
Lower respiratory tract specimens, such as sputum, bronchoal-
veolar lavage, and tracheal aspirates, should be collected. If 
possible, the collection of nasopharyngeal and oropharyngeal 
swabs can be considered.
Patients referred for additional testing by a physician (e.g., patients 
who tested negative using nasopharyngeal or oropharyngeal swabs, 
but show an indication of pneumonia)
Lower respiratory tract specimens, such as sputum, bronchoal-
veolar lavage, and tracheal aspirates, should be collected.
Other specimens
If necessary, additional specimens, such as blood, urine, and 
feces, may be collected on consultation with the physician tak-
ing care of the patient and a laboratory physician. However, the 
diagnostic value and clinical utility of these specimens remain 
unclear. The collection of blood specimens may be considered 
for public health purposes, such as serological surveys. This 
may be amended based on new clinical evidence.
Safety procedures during specimen collection
The guidelines for the prevention of infection and control for aero-
sol-producing procedures should be followed when collecting 
specimens using aerosol-producing procedures, such as sputum 
collection, tracheal aspiration, and bronchoscopy (Table 3).
Collection of upper respiratory tract specimens, especially na-
sopharyngeal swab specimens, requires knowledge of the ana-
tomical structure of the respiratory system and the collection 
process is also invasive. Hence, it is recommended that the col-
lection be performed by medical personnel.
When collecting blood and other non-respiratory specimens 
from suspected or confirmed COVID-19 patients, laboratory per-
sonnel should wear personal protective equipment (PPE; N95 
or KF94 mask, disposable gloves, gown [clean, covering the en-
tire body, long-sleeves, back-closure], and eye protection [gog-
gles or face shield]).
SPECIMEN PACKING AND TRANSPORT
Specimen packing and transport within medical institutions 
[18–20]
-  The primary container should be sealed with a screw cap. 
The container should be made of plastic that has a low risk 
of breakage (e.g., a 50 mL conical tube or a VTM containing 
a cotton swab).
-  Patient information should be recorded on the specimen 
container using two or more identifiers (e.g., name, patient 
number), along with the necessary information for testing 
requests. If the specimen information is erased on the bar-
code following disinfection with ethanol or is damaged, it 
should be recorded again for easy and accurate identifica-
tion.
-  The outer surface of the primary container should be disin-
fected using appropriate disinfectants such as 70% ethanol. 
The container should be packed in a zipper bag and placed 
in a secondary container before transportation. The second-
ary container should be sealed and shock-resistant and 
should be labeled to indicate that it contains infectious sub-
Table 3. Infection prevention and control for aerosol-producing procedures [28–30]    
Aerosol-producing procedures
- Sputum collection, tracheal aspiration, bronchoscopy, continuous positive airway pressure therapy, removal of tracheal intubation, etc.
Principles of infection prevention and control 
- Patient care should be performed with minimal medical staff.
-  The following PPE should be used by personnel: N95 or KF94 mask or equivalent respirators, protective gown, disposable gloves, and eye protection (goggles or face 
shield).
- Personnel should adhere to the facility’s hand hygiene policy before and after patient contact, as well as after removing PPE.
Procedure site
-  A single, negative pressure room with >12 air changes/hr is recommended for patient care. When this cannot be made available, a single room with natural 
ventilation and an average ventilation rate of 160 L/sec/patient can be used. 
-  After using the single room, it should be disinfected according to the defined procedure and left vacant for a period of approximately 30 min (considering an air 
circulation rate of 12 air changes/hr).
- Entry to/exit from the room should be minimized during the procedure. 
Abbreviation: PPE, personal protective equipment.
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stances. 
-  When transporting specimens to a laboratory within the 
same institution, the specimens should be transported in 
person; the pneumatic tube system should not be used. A 
separate route should be used for transportation; it is recom-
mended that an elevator be exclusively designated for such 
transportation. The personnel transporting the specimen 
should be trained in spill decontamination procedures in 
case of specimen leakage.
-  If there are no visible leaks in the secondary container on re-
ceipt of a specimen, it can be reused after being disinfected 
using appropriate disinfectants such as 70% ethanol. 
External transport [19–21]
-  The triple packaging system (the UN3373 P650 packaging 
instructions) should be used.
-  The primary container should be sealed with a screw cap and 
should be made of plastic that has a low risk of breakage.
-  The outer surface of the primary container should be steril-
ized using appropriate disinfectants such as 70% ethanol. 
The primary container should be covered with  enough ab-
sorbent material and placed in a secondary container with 
the cap of the primary container facing upwards. The sec-
ondary container should be sealed with a sturdy cap such 
as a screw cap with an O-ring for waterproof and leakproof 
protection. The amount of absorbent should be enough to 
absorb the entire contents of the primary container in case 
of leakage. 
-  Cushioning materials, such as bubble wrap, should be 
placed in the outer packaging to reduce external impact 
during transportation. The secondary container should be 
fixed to prevent shaking. The specimen information sheet 
and the test request form should be placed between the 
secondary container and outer packaging. If necessary, in-
formation regarding the contents and amount of infectious 
material should be attached to the surface of the secondary 
container. 
-  The surface of the tertiary container should display the 
sender and recipient contact details, in case of emergency, 
as well as a UN3373 label indicating a Category B infectious 
substance.
-  For further detailed guidelines not provided here, please re-
fer to the latest edition of the “Guidance for laboratory bio-
safety related to coronavirus disease 2019” available on the 
KCDC website [21].
SPECIMEN HANDLING AND TESTING 
PROCEDURES [14, 15, 20–25]
-  Personnel collecting the specimens should wear appropriate 
PPE (N95, KF94, or equivalent respirators, protective cloth-
ing, disposable gloves, etc.) and handle the specimens in a 
Class II or higher biosafety cabinet (BSC) at a biosafety level 
2 (BL2) laboratory. Aerosol-producing procedures should al-
ways be performed within the BSC. If the container has to 
be opened outside of the BSC, PPE, such as an N95, KF94, 
or a higher-grade respirator (powered air-purifying respirator 
recommended), should be worn by the personnel and the 
bench should be disinfected after the procedure. 
-  Specimens that are subjected to nucleic acid extraction or 
inactivation in the BSC can be handled outside of the BSC 
in accordance with standard precautions for conventional 
specimens. 
-  The test method should comply with the standard operating 
procedures used by each laboratory and the manufacturer’s 
instructions. Currently, clinical laboratories are using various 
nucleic acid extraction methods and reagents for real-time 
RT-PCR with EUA for COVID-19 diagnosis, and there are vari-
ations in the procedures used for the diagnosis. These guide-
lines do not present opinions regarding the selection of spe-
cific test methods or detailed test items. KSLM provides ex-
pert opinions on the detailed test items in the Q&A section 
of its website (http://www.kslm.org/rang_board/list.html?code= 
covid19_qna).
-  When using commercially available products, the manufac-
turer’s instructions and all other appropriate measures 
should be followed and care should be taken to prevent 
cross-contamination during nucleic acid extraction and ad-
dition to reagents. All procedures should comply with labo-
ratory biosafety guidelines. Personnel should wear PPE (N95 
or KF94 mask, disposable gloves, gown [covering the entire 
body, long-sleeves, and back-closure], and eye protection) 
in an isolated BL2 or higher laboratory. The use of auto-
mated equipment for nucleic acid extraction, which enables 
extraction outside of the BSC, is recommended. If an auto-
mated nucleic acid extraction system is not used, the proce-
dure should be performed in a Class II or higher BSC.
-  At the end of the procedure or when the specimen is con-
taminated, the bench should be disinfected using appropri-
ate disinfectants (70% ethanol, 2% glutaraldehyde, sodium 
hypochlorite [chlorine concentration 0.05%, 500 ppm], or 
other common virus disinfectants). Other disinfectants ap-
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proved by the Korea Ministry of Environment may also be 
used. The manufacturer’s recommendations for dilutions 
and contact times should be followed. 
-  Waste handling: all infectious waste, including residual 
specimens, should be disposed off in accordance with the 
Korea Ministry of Environment’s guidelines [25]. Residual 
specimens that tested negative using the COVID-19 testing 
can be disposed off according to the Ministry of Environ-
ment’s guidelines for disposal of waste generated during 
routine testing. 
TEST INTERPRETATION 
General guidelines for interpreting COVID-19 real-time RT-
PCR*
*Intended for commercial kits with EUA as of March 25, 2020
Criteria for determining positive and negative results in the 
screening and confirmatory tests
Positive control (+), negative control (-)
-  Threshold cycle (Ct) value of the target gene ≤cut-off Ct value: 
positive for the gene*.
-  No target gene detected or Ct value >cut-off Ct value: nega-
tive for the gene*.
*Independent of internal control amplification
All results of negative control (+) or positive control (-)
Invalid regardless of target gene and internal control amplifica-
tion; retest is necessary. See details below.
Note: Values close to the cut-off values in specimens with low 
viral loads may indicate false-negative or false-positive results. 
Thus, a laboratory physician should interpret the results and if 
necessary, retest using residual or new specimens. 
Criteria for final test interpretation 
All kits currently available in Korea can detect two or more 
genes. According to the interpretation criteria of some manufac-
turers, detection of only one of multiple genes is interpreted as 
COVID-19 positive. However, based on results from actual clini-
cal specimens, KSLM recommends a determination of a posi-
tive result only when all genes are detected. When only one 
gene is detected, retesting or consulting the reference laboratory 
is recommended.
1)  Screening test (+) and confirmatory test (+): positive for 
COVID-19 (SARS-CoV-2 detected).
 Among the reagents with EUA, some kits with three target 
genes use one target gene for the screening test and the 
other two target genes for the confirmatory test. For these 
kits, the confirmatory test result is deemed positive only if 
both confirmatory genes are detected. If one gene is not 
detected, the result cannot be interpreted as positive. 
2)  Screening test (+) and confirmatory test (-): negative for 
COVID-19 (SARS-CoV-2 not detected).
 For kits using betacoronavirus primers for the screening 
test, there is a possibility of betacoronavirus rather than 
SARS-CoV-2.
3)  Screening test (-) and confirmatory test (-): negative for 
COVID-19 (SARS-CoV-2 not detected).
 If the internal control is also negative, the result is invalid, 
and a retest is necessary.
4)  Screening test (-) and confirmatory test (+): retest or refer 
to a reference laboratory for additional testing.
Considerations
At present, there is very limited knowledge regarding the timing 
of virus detection in COVID-19 cases. Hence, it is difficult to rule 
out COVID-19 based solely on one negative result, especially 
when using an upper respiratory tract specimen from a sus-
pected case. Other upper respiratory tract specimens should be 
collected and tested when a highly suspected COVID-19 patient 
tests negative using a single upper respiratory tract specimen. 
The lower respiratory tract specimens may be collected together 
and tested. Some considerations for possible false negative re-
sults are listed below:
Possible causes of false negative results [4, 26]
- Inadequate specimen quality.
- Specimens collected too early or too late.
- Specimens improperly handled or transported.
- Occurrence of viral genetic mutation.
- Presence of PCR inhibitors.
- Antiviral administration prior to testing.
Solutions
-  If the upper respiratory tract specimens test negative, lower 
respiratory tract specimens should be collected and tested. 
-  Patient specimens, a positive control, and a negative control 
should be examined together, and internal controls should 
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be examined and verified together in all reactions.
-  If a patient with an epidemiological correlation and COVID-19 
symptoms repeatedly tests negative, the tested specimen 
should be submitted to the KCDC for further testing. 
REPORT [26]
(1) Basic information regarding the collected specimen
      Patient name, age (date of birth), sex, patient number (hos-
pital number), specimen number, ward, test order date, speci-
men type, and specimen collection time.
(2) Results
- Negative
-  Indeterminate, Inconclusive, Equivocal*: retesting is recom-
mended using new specimens.
   * These guidelines do not clearly differentiate these terms. 
The laboratory physician can decide the term to use.
-  Positive: should be reported immediately.
(3)  Note: Any unusual findings such as those regarding 
specimen quality.
(4) Reporting time
LABORATORY GUIDELINES FOR BIOSAFETY 
AND INFECTION CONTROL
General information [14, 15, 20–24, 27–29]
PPE
-  The personnel collecting the specimens should follow the 
standard precautions for handling all potentially infectious 
specimens. The personnel should wear disposable gloves, a 
gown (covering the entire body, long-sleeved, and contain-
ing a back-closure), mask (surgical mask, dental mask, 
etc.), and goggles or face shield (should be worn on top of 
the glasses when there is a risk of splashing from opening 
the specimen container). 
-  When there is a high risk of aerosol production, respiratory 
protection higher than N95 or KF94 should be used. When 
wearing a respirator, a fit test should always be employed to 
ensure proper usage. 
-  The use of respirators and face masks is not necessary 
when working inside a BSC; however, they can still be used 
considering the additional risks. 
-  Once testing is completed, all protective equipment should 
be removed, and hands should be washed before leaving 
the testing area.
-  Protective equipment should be removed carefully so as not 
to contaminate the hands and body.
Working area and equipment
-  Aerosol-generating procedures (e.g., vortex agitation) should 
be performed inside a certified Class II or higher BSC. Cen-
trifuges should be equipped with a double cover, safety 
buckets, and sealed rotors, which are physically sealed and 
require the insertion or removal of centrifuge tubes into 
buckets and rotors for centrifugation. Procedures conducted 
outside of the BSC should ensure minimal exposure. 
-  After handling the specimens, the work area and equipment 
should be disinfected with 70% ethanol or other suitable 
disinfectants. 
-  Consumables that are contacted with infectious specimens 
should be disposable. 
-  All infectious waste should be disposed off in accordance 
with the Ministry of Environment’s “Specific measures for 
the management of coronavirus disease 2019 quarantine 
medical waste” guidelines [25]. 
-  Residual specimens that test negative in the COVID-19 test-
ing can be disposed off following the Ministry of Environ-
ment’s guidelines for disposal of waste generated during 
routine testing [24].
COVID-19 biosafety measures [14, 15, 20–24, 27]
The following procedures should be performed only in BL3 or higher 
facilities
-  Virus isolation in cell culture.
-  Manipulation of live virus isolates.
The following procedures should be performed only in BL2 or higher 
facilities and in a certified Class II or higher BSC
-  Aliquoting or diluting specimens.
-  Inoculating bacterial or mycological culture media.
-  Performing diagnostic testing that does not involve the prop-
agation of viral agents. 
-  Nucleic acid extraction procedures for infectious specimens.
-  Preparation and chemical- or heat-fixing of smears for mi-
croscopic testing.
-  Rapid antigen test on urine or respiratory specimens.
The following procedures should be performed in BL2 or higher 
facilities
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-  Pathological examination of formalin-fixed or otherwise inac-
tivated tissues.
-  Molecular testing of extracted nucleic acid preparations.
-  Electron microscopy examination of glutaraldehyde-fixed 
specimens.
-  Routine examination of bacterial and fungal cultures.
- Microscopy of fixed specimens.
-  Final packaging of infectious specimens already sealed in a 
secondary container.
-  Procedures using inactivated specimens (e.g., specimens in 
nucleic acid extraction buffer).
Routine tests (hematological tests, biochemical tests, etc.)
-  When performing routine tests (hematological tests, bio-
chemical tests, serological tests, etc.) on blood, serum, or 
urine specimens, after performing a risk assessment consid-
ering the risk of infectious aerosol, the specimens can be 
handled in the same way as that used for general clinical 
specimens in appropriate cases. 
-  In general, decapping is considered a low-risk procedure. 
However, it depends on the design of the lid and container. 
Whether to proceed with the testing will be determined fol-
lowing a risk assessment, which takes into account the need 
for centrifugation, mixing, and aliquoting. In addition, the 
use of a BSC should be considered at any time when there 
is a high risk. 
-  Point-of-care testing, such as blood-gas analysis, should 
also be performed once safety is confirmed through a risk 
assessment.
-  Automated analyzers should be sterilized according to the 
laboratory manual after specimen treatment or before regu-
lar maintenance checks.
-  A certified BSC should be used while counting cells or mak-
ing smears using body fluids other than blood (e.g., cerebro-
spinal fluid). 
-  Respiratory specimens and any other specimens should be 
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